| | | | | | |

UK Study Finds Location Influences Mesothelioma Survival

1816251_UKAn analysis of the largest ever study group of mesothelioma patients suggests that survival may depend largely on how much experience a patient’s local hospital has with the disease.

The study was conducted at six different hospitals or universities in England and included 8,740 mesothelioma patients whose data was collected for the UK National Lung Cancer Audit. The group represented about 80 percent of the total mesothelioma cases in the region between 2008 and 2012. Most of the patients (83%) were men and their median age was 73.

The researchers found significant differences in the way mesothelioma cases were handled in different parts of the country. These differences appeared to have an impact on mesothelioma outcomes. For instance, while performance status (PS), a reflection of a patient’s overall health status, was recorded in 81 percent of cases, cancer stage was not. Stage is a measurement of how far mesothelioma has spread and has a direct impact on treatment approach and survival, but the researchers say it was “poorly recorded and unreliable in this dataset.”

Of the 8,740 mesothelioma patients studied, 87 percent received a definitive diagnosis based on advanced histo-cytological test results. Only 67 percent receive anti-cancer treatment. The researchers say the types of treatments used tended to reflect the findings of the most recently published mesothelioma trials; use of chemotherapy appeared to be on the rise from year to year while use of radical surgery appeared to decline.

The overall median survival among all the mesothelioma patients studied was 9.5 months with a 1 year survival rate of 41.4% and a 3 year survival rate of 12%. Median survival had improved by about a month between patients treated in 2008 and those treated in 2012. As has been the case in previous mesothelioma studies, survival was closely linked to PS and histological subtype. However, there was a significant range in the median survival rates between various cancer centers – from 209 days to 349.

“There is a significant variation in care patterns and outcomes that may reflect limited expertise in areas with low incidence [of mesothelioma],” speculates study author Paul Beckett of the Royal College of Physicians in London in the journal Lung Cancer. Dr. Beckett and his colleagues say initiatives designed to get more UK doctors to measure and record mesothelioma stage could be a start to improve outcomes.

Great Britain has one of the highest per capita rates of mesothelioma in the world, largely due to the prevalence of asbestos in building materials after World War II.

Surviving Mesothelioma maintains a large list of some of the top mesothelioma experts in the US See the Doctors section to find an experienced clinician in your region.

Source:

Beckett, P et al, “Demographics, management and survival of patients with malignant pleural mesothelioma in the National Lung Cancer Audit in England and Wales”, March 30, 2015, Lung Cancer, Epub ahead of print

Similar Posts

  • | |

    Mesothelioma survivor Paul Kraus, alive and well 19 years after writing “Surviving Mesothelioma and Other Cancers

    Paul Kraus is considered the longest documented mesothelioma survivor in the world. He was diagnosed in 1997 with mesothelioma so widespread that he was given little hope of survival. Not willing to give up, he worked with a team of doctors to create his own tailored treatment protocol. This protocol included dramatic life style change, experimental therapies, dietary changes, mind-body medicine, and other modalities. Paul was fortunate. The protocol he and his doctors created helped him keep the mesothelioma in check. His book “Surviving Mesothelioma and Other Cancers: A Patient’s Guide” details his cancer voyage, the decisions he made, and his philosophies about health and healing. This book is now the best-selling mesothelioma book in the world and has inspired…

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • |

    Mesothelioma Still Rising Despite Ban in Ireland

    A study in Ireland confirms that it can take many years for a ban on asbestos to have a measurable impact on a country’s rates of malignant mesothelioma. Mesothelioma is the most serious of a list of diseases – including lung cancer, pleural plaques, asbestosis, and others – linked with exposure to asbestos dust. Affecting the linings around the lungs and other organs, mesothelioma is often resistant to most cancer treatments and may be fatal within a year of diagnosis. According to the International Ban Asbestos Secretariat, Ireland is one of 55 countries that have enacted some type of asbestos ban. However, although Ireland banned asbestos in 2000, a new study published in Cancer Epidemiology shows that incidence of the…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • |

    Website Aims to Protect Homeowners from Mesothelioma

    Australia’s Cancer Council is trying to educate home renovators about their risk for mesothelioma with a new e-learning course. Australia has one of the highest per capita rates of mesothelioma in the world, largely because of several asbestos mining operations that were once located there. Although asbestos has been banned from building products in Australia since 1989, asbestos-linked diseases like mesothelioma, lung cancer, and asbestosis continue to pose a serious health concern. While mesothelioma has traditionally occurred among people exposed to asbestos on the job, Australia is now bracing for another “wave” of mesothelioma victims among homeowners who encounter asbestos while doing their own renovation projects. Cancer Council Australia has launched “kNOw asbestos in your home” in an effort to…

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…